November 4, 2020
Tetra Therapeutics, now a wholly owned US subsidiary of Shionogi, on November 2 announced positive topline results from its PII exploratory study conducted in the US to test its cognitive disorder treatment BPN14770 in adult patients with fragile X syndrome...read more